This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Relias, V. Articles by Andrew Skirvin, J. Search for Related Content PubMed Articles by Relias, V. Articles by Andrew Skirvin, J. Social Bookmarking                         What's this?

Review : Topoisomerase I inhibitors: 1. Topotecan

New England Medical Center, Department of Pharmacy, Boston, Massachusetts

J. Andrew Skirvin, PharmD

St. John's University, College of Pharmacy, Jamaica, New York

Purpose. The primary objective of this article is to discuss the pharmacology, pharmacokinetics, clin ical use, and adverse effects of the approved topoisomerase I inhibitors. This is the first in a series of two articles and will focus on topotecan.

Data Sources. We reviewed the literature through a MEDLINE search of English language articles from 1985 through 1997. Relevant articles cited in the titles obtained from the MEDLINE search were also used. The following terms were used for purpose of conducting the MEDLINE search: topoisomerase inhibitors, topotecan, topo isomerase I, Hycamtin, SKF 104864.

Data Extraction. We reviewed the current literature in order to discuss the pharmacology, pharmacokinetics, clinical use, toxicity, drug inter actions, indications, formulation, dosage and ad ministration, and pharmaceutical issues surround ing the use of topotecan.

Data Synthesis. The topoisomerase I inhibi tors are new antineoplastic agents with a unique mechanism of action. Promising areas of applica tion include ovarian cancer, lung cancer, radiation sensitization, and refractory leukemias. Clinical tri als detailing its activity in these areas are pre sented.

Key Words: Topotecan • topoisomerase inhibitor • camptothecins.

Journal of Oncology Pharmacy Practice, Vol. 3, No. 4, 173-185 (1997)
DOI: 10.1177/107815529700300401


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?